Quidel - QDEL STOCK NEWS

Quidel Corporation (NASDAQ: QDEL) reported fourth quarter 2021 revenue of $636.9 million, a decline from $809.2 million in 2020, primarily due to a $249 million drop in Sofia product sales. Although COVID-19 product revenue increased 42% to $1.27 billion for the year, GAAP EPS decreased to $6.85, down from $10.78 in Q4 2020. The company is expanding into retail testing markets and has a definitive agreement to acquire Ortho Clinical Diagnostics. Full year gross profit was $1.27 billion, down from $1.34 billion in 2020.

Quidel Corporation (NASDAQ: QDEL) will release its fiscal fourth quarter and full-year 2021 financial results on February 17, 2022, after market close. Following this, CEO Douglas Bryant and CFO Randy Steward will host a conference call at 5:00 p.m. ET to discuss the results and answer investor questions. The call will cover business developments and financial trends, with material information likely included. Investors can join by phone or via a webcast, with replays accessible for one year for the webcast and 14 days for the phone replay.

Quidel Corporation (NASDAQ: QDEL) announced projected revenues for Q4 2021 between $633 million and $637 million, with COVID-19 revenues expected around $510 million. The company highlights significant achievements in 2021, including the opening of a major immunoassay manufacturing facility and the acquisition agreement for Ortho Clinical Diagnostics. Quidel sold nearly 77 million rapid tests in Q4 and plans to enhance its product offerings in 2022 with the introduction of new technologies.

Quidel Corporation (NASDAQ: QDEL) announces the availability of a public health webinar on Bartonella species, the cause of Bartonellosis. Conducted by Dr. Monica E. Embers, the webinar discusses clinical presentations of Bartonellosis, its comparison with Lyme disease, and highlights research needs for better diagnosis and treatment. The event is relevant as Lyme disease cases surged to nearly 476,000 in 2021. Quidel, a leader in diagnostic solutions, aims to enhance healthcare through rapid testing technologies.

Quidel Corporation (NASDAQ: QDEL) will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 1:30 p.m. Eastern time. Douglas Bryant, the CEO, will discuss the company's business and financial developments, followed by a Q&A session. A live webcast of the presentation will be available on Quidel's Investor Relations website, along with an audio archive for 14 days post-event. Quidel is a leader in rapid diagnostic testing solutions and aims to enhance global healthcare quality.

Quidel Corporation (NASDAQ: QDEL) reports its antigen tests, including QuickVue and Sofia, effectively detect the Omicron variant of COVID-19. CEO Douglas Bryant noted ongoing evaluations using live samples confirm prior findings from FDA RADx studies. Quidel is increasing production of its antigen tests to enhance community access. The company remains committed to monitoring COVID-19 variants to assure product efficacy. With over 40 years in diagnostics, Quidel continues to lead in rapid testing solutions.

Quidel Corporation (NASDAQ: QDEL) has announced a definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) for $24.68 per share, totaling approximately $6 billion. This acquisition, representing a 25% premium over Ortho's prior closing price, aims to enhance Quidel's diagnostic capabilities across over 130 countries. The transaction is expected to yield annual cost synergies of $90 million and revenue synergies exceeding $100 million by 2025, enhancing Quidel's product innovation and operational efficiency.

Quidel Corporation (NASDAQ: QDEL) has secured a multi-year partnership with the Chicago Blackhawks to promote community health initiatives. This partnership features the donation of QuickVue At-Home OTC COVID-19 Tests to community partners, aiming to enhance healthcare access for local youth. The QuickVue test yields results in 10 minutes, demonstrating a proven accuracy of 83.5% for positive results and 99.2% for negative results. Additionally, the partnership includes marketing opportunities during games, reflecting Quidel's commitment to equitable healthcare.

Quidel has launched a series of infographics to educate Americans about Lyme disease, which affects nearly 480,000 individuals annually. The resources detail characteristics, warning signs, and areas of prevalence, emphasizing the importance of awareness for outdoor enthusiasts. Quidel's Sofia® 2 Lyme FIA test offers results within 15 minutes, a significant improvement over traditional testing methods. The infographics and additional educational content are available at LymeDiseaseAnswers.com.